Study period | January 2007–December 2013 | January 2014–December 2015 |
Subjects | 30 | 18 |
Sex | | |
Male | 19 | 9 |
Female | 11 | 9 |
Race | | |
Caucasian | 28 | 15 |
African-American | 1 | 1 |
Other | 1 | 2 |
Fluconazole use | | |
Yes | 15 | 16 |
No | 15 | 2 |
Age (year) | | |
Median (range) | 5.7 (0.1 to 17.7) | 2.0 (0.3 to 18.4) |
Weight (kg) | | |
Median (range) | 28.9 (7.0 to 77.2) | 11.2 (4.9 to 63.0) |
Creatinine clearance (mL/min/1.73 m2) | | |
Median (range) | 122.4 (15.6 to 442.2) | 104.7 (8.5 to 224.9) |
Transplant indications | | |
Congenital heart disease | 14 | 8 |
Cardiomyopathy | 16 | 9 |
Arrhythmia | 0 | 1 |
Dose (mg/kg/day) | | |
Median (range) | 0.09 (0.02 to 0.49) | 0.17 (0.03 to 0.69) |
Concentration (µg/L) | | |
Median (range) | 12.7 (1.5 to 32.7) | 13.4 (2.5 to 37.7) |
<12 µg/L | 41% | 36% |
12 to 16 µg/L | 39% | 40% |
>16 µg/L | 20% | 24% |